Singapore markets close in 4 hours 33 minutes
  • Straits Times Index

    3,279.79
    -0.25 (-0.01%)
     
  • Nikkei

    27,621.76
    -635.49 (-2.25%)
     
  • Hang Seng

    24,117.26
    +4.48 (+0.02%)
     
  • FTSE 100

    7,563.55
    -47.68 (-0.63%)
     
  • BTC-USD

    41,710.96
    -283.57 (-0.68%)
     
  • CMC Crypto 200

    992.80
    -16.59 (-1.64%)
     
  • S&P 500

    4,577.11
    -85.74 (-1.84%)
     
  • Dow

    35,368.47
    -543.34 (-1.51%)
     
  • Nasdaq

    14,506.90
    -386.86 (-2.60%)
     
  • Gold

    1,811.10
    -1.30 (-0.07%)
     
  • Crude Oil

    86.54
    +1.11 (+1.30%)
     
  • 10-Yr Bond

    1.8650
    +0.0930 (+5.25%)
     
  • FTSE Bursa Malaysia

    1,528.76
    -14.16 (-0.92%)
     
  • Jakarta Composite Index

    6,607.74
    -6.32 (-0.10%)
     
  • PSE Index

    7,283.08
    -60.88 (-0.83%)
     

Why 23andMe Rocketed 27.9% Higher in October

·2-min read
Why 23andMe Rocketed 27.9% Higher in October
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

Shares of 23andMe (NASDAQ: ME) jumped 27.9% in October, according to data from S&P Global Market Intelligence. The consumer genetics and pharmaceutical research company announced an acquisition of the telehealth platform Lemonaid Health for $400 million last month, which is the main news that drove up the stock price. 23andMe is the company behind the popular genetic testing kits where consumers can learn about their ancestry background and genetic health.

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting